Supernus Pharmaceuticals, Inc.
SUPN
$48.27
$1.122.38%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 830.44M | 776.83M | 718.95M | 681.54M | 665.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 830.44M | 776.83M | 718.95M | 681.54M | 665.13M |
| Cost of Revenue | 225.13M | 200.94M | 180.80M | 184.71M | 183.00M |
| Gross Profit | 605.31M | 575.90M | 538.16M | 496.83M | 482.13M |
| SG&A Expenses | 498.12M | 456.64M | 424.31M | 381.48M | 351.76M |
| Depreciation & Amortization | 99.83M | 95.31M | 89.46M | 83.17M | 78.34M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 823.08M | 752.89M | 694.56M | 649.36M | 613.09M |
| Operating Income | 7.36M | 23.95M | 24.39M | 32.18M | 52.04M |
| Income Before Tax | -123.47M | -49.15M | -49.03M | -20.73M | 82.16M |
| Income Tax Expenses | -13.58M | -20.13M | -10.48M | -1.62M | 17.67M |
| Earnings from Continuing Operations | -109.89 | -29.02 | -38.55 | -19.12 | 64.50 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -109.89M | -29.02M | -38.55M | -19.12M | 64.50M |
| EBIT | 7.36M | 23.95M | 24.39M | 32.18M | 52.04M |
| EBITDA | 109.06M | 121.26M | 115.96M | 117.57M | 132.72M |
| EPS Basic | -1.91 | -0.51 | -0.68 | -0.33 | 1.16 |
| Normalized Basic EPS | 0.16 | 0.39 | 0.42 | 0.54 | 0.79 |
| EPS Diluted | -1.92 | -0.51 | -0.68 | -0.34 | 1.15 |
| Normalized Diluted EPS | 0.16 | 0.39 | 0.42 | 0.53 | 0.78 |
| Average Basic Shares Outstanding | 229.61M | 227.57M | 225.79M | 223.91M | 222.50M |
| Average Diluted Shares Outstanding | 229.61M | 228.19M | 226.40M | 225.53M | 224.99M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |